Portola Anticipates “Best In Class” Status For Novel Phase II Anticoagulant
This article was originally published in The Pink Sheet Daily
Executive Summary
Privately held biotech cites betrixaban’s potential for daily dosing and safety in renally-impaired patients as differentiation points from other candidates.
You may also be interested in...
Portola Marries Factor Xa Clot Buster Off To Merck
Deal is "strikingly similar" to a collaboration forged with Novartis for an anti-thrombotic earlier this year.
Portola Marries Factor Xa Clot Buster Off To Merck
Deal is "strikingly similar" to a collaboration forged with Novartis for an anti-thrombotic earlier this year.
Coulda, Shoulda? Sanofi's Skip On Portola Proves Clot-Buster Gain For Novartis
Deal could complicate venture investors' exit, though Portola thinks not – as another would-be partner eyes second lead product.